Gemcitabine-induced digital necrosis in a patient with cervical squamous cell carcinoma: case report and literature review
Abstract
Objectives: To present the case of a patient with squamous cell carcinoma of the cervix who developed distal necrosis following treatment with gemcitabine, and to perform a literature review to assess the association between the cumulative dose of gemcitabine, diagnosis, and management of this complication.
Material and methods: A 61 year old patient was treated with gemcitabine (total accumulated dose of 11,744 mg/m²) for metastatic disease at a private, nononcological, fourth level general hospital, where she was receiving outpatient management. She developed distal necrosis of the second finger on her right hand, leading to the discontinuation of gemcitabine and necessitating amputation of the affected finger. A search was conducted in Embase, Medline, and Lilacs for case reports and case series on gemcitabine induced distal necrosis. Data on dosage, diagnosis, and treatment were extracted.
Results: Fifteen case reports including 19 cases of distal necrosis were identified. The cumulative doses of gemcitabine ranged from 1,700 to 28,700 mg/m². Diagnosis was primarily clinical, supplemented by angiography and Doppler ultrasound; treatment included discontinuation of gemcitabine, initiation of vasodilators, anticoagulants, and symptomatic management.
Conclusions: It is essential to recognize vascular toxicity as a potential adverse effect of gemcitabine and to conduct appropriate risk stratification in patients with advanced cancer and multiple prior treatment lines.…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.